2025 India Anti-Tuberculosis Drug Market Revenue Opportunities Report
Description
The 2025 India Anti-Tuberculosis Drug Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Tuberculosis Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-tuberculosis (TB) drug market in India are Lupin Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, and Cipla Limited. Lupin is a major manufacturer of anti-TB drugs, including active pharmaceutical ingredients (APIs) like ethambutol and pyrazinamide, and is heavily involved in global TB drug supply and innovation aligned with WHO strategies. Sun Pharma is a pharmaceutical giant with advanced product development capabilities and supplies a broad range of pharmaceutical formulations, including for TB treatment. Aurobindo Pharma operates 27 manufacturing facilities and exports across 150 countries, contributing significantly to TB drug availability. Cipla is another key Indian player, known for essential affordable anti-TB drugs widely used in India and globally.
These companies lead in both production and innovation in anti-TB therapies, including first-line and drug-resistant tuberculosis treatment options. For instance, Mylan (now part of Viatris) recently secured Indian regulatory approval for pretomanid, a novel drug for highly drug-resistant TB, underscoring the importance of Indian manufacturers in combating drug-resistant TB. Collectively, these firms work closely with national programs like India's National Tuberculosis Elimination Program (NTEP) and international partners to enhance drug accessibility, affordability, and quality assurance. Their efforts include manufacturing fixed-dose combinations (FDCs), scaling up quality control, and integrating newer drugs into TB care to curb the disease burden in India, the largest TB market globally.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Tuberculosis Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-tuberculosis (TB) drug market in India are Lupin Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, and Cipla Limited. Lupin is a major manufacturer of anti-TB drugs, including active pharmaceutical ingredients (APIs) like ethambutol and pyrazinamide, and is heavily involved in global TB drug supply and innovation aligned with WHO strategies. Sun Pharma is a pharmaceutical giant with advanced product development capabilities and supplies a broad range of pharmaceutical formulations, including for TB treatment. Aurobindo Pharma operates 27 manufacturing facilities and exports across 150 countries, contributing significantly to TB drug availability. Cipla is another key Indian player, known for essential affordable anti-TB drugs widely used in India and globally.
These companies lead in both production and innovation in anti-TB therapies, including first-line and drug-resistant tuberculosis treatment options. For instance, Mylan (now part of Viatris) recently secured Indian regulatory approval for pretomanid, a novel drug for highly drug-resistant TB, underscoring the importance of Indian manufacturers in combating drug-resistant TB. Collectively, these firms work closely with national programs like India's National Tuberculosis Elimination Program (NTEP) and international partners to enhance drug accessibility, affordability, and quality assurance. Their efforts include manufacturing fixed-dose combinations (FDCs), scaling up quality control, and integrating newer drugs into TB care to curb the disease burden in India, the largest TB market globally.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
